In the span of a single year, the FDA approved ten molecularly targeted cancer therapies — each one designed not to overwhelm the body, but to find and dismantle the specific molecular machinery driving a patient's disease. The 2026 AACR Cancer Progress Report frames this acceleration against a sobering horizon: over 626,000 projected American deaths this year, and a cancer burden expected to grow nearly a fifth by 2050. Among the approvals stands vepdegestrant, the first drug of an entirely new class — PROTACs — that commandeers the cell's own disposal system to eliminate cancerous proteins,
AACR Report: FDA Approves 10 Targeted Cancer Therapies in 12 Months
Over 626,000 cancer deaths projected in the United States in 2026; disparities in access to targeted therapies and diagnostics limit treatment benefits for certain populations.
Precision medicine is expanding, but not equally.
Mark
So ten new drugs in twelve months—that's the headline. But what does that actually mean for someone sitting in an oncologist's office right now?
Mimi
It means their doctor has more tools, and more of those tools are built for their specific cancer. If you have that ESR1 mutation in breast cancer, vepdegestrant is designed for you. It's not a broad chemotherapy; it's targeted.
Luke
But here's the thing—those ten approvals span six different cancer types. That's not ten new options for one patient; it's one or two new options scattered across the landscape. And the report itself says access disparities are a barrier. So the approvals exist, but not everyone can get them.
Mark
What's a companion diagnostic, and why does it matter so much?
Mimi
It's a test that tells you whether your tumor has the specific mutation that a drug targets. So before you take vepdegestrant, you need the Guardant360 test to confirm you have the ESR1 mutation. Without it, the drug won't work for you.
Luke
And that test costs money. It requires tissue or blood samples, lab processing, turnaround time. The report notes that disparities in access to biomarker testing exist—that's the polite way of saying some patients won't get tested at all.
Mark
The report mentions treatment resistance. What does that mean?
Mimi
Even when a targeted drug works beautifully at first, the cancer can evolve and develop resistance. The drug stops working. It's not a permanent solution; it's a temporary advantage.
Luke
The report doesn't quantify how often that happens or how long the benefit typically lasts. It names the problem but doesn't measure it. That's important to know before you think these approvals are cures.
Mark
What about the cancer burden itself—the numbers in the report?
Mimi
Over 2.1 million new cases expected in 2026, 626,000 deaths. And by 2050, cases are projected to jump nineteen percent to 2.5 million annually. The burden is growing.
Luke
Those are projections, not certainties. They're based on current trends and demographic models. But they're the best estimates we have, and they show why speed in drug development matters—the need is real and it's accelerating.
Il Polso
- Ten FDA-approved targeted therapies in twelve months — including the world's first PROTAC drug — signal that cancer treatment is advancing faster than at almost any prior moment in oncology history.
- With 2.1 million new diagnoses expected in 2026 and a 19% rise in cases projected by 2050, the pace of approvals feels less like progress and more like a race against a growing tide.
- Companion diagnostics have become the gatekeepers of modern care, required alongside many new therapies to confirm which patients carry the precise mutations a drug is built to target — collapsing the old model of one-size-fits-all treatment.
- Breakthroughs span multiple fronts: new lung cancer therapies targeting HER2 and EGFR mutations, a first-ever systemic option for a deadly brain tumor, and a new class of blood cancer treatment — the breadth of precision medicine is widening rapidly.
- Yet access remains the fracture line — not every patient can obtain biomarker testing, not every diagnosis leads to a matched therapy, and even effective drugs can lose their power as cancers evolve and resist.
- The report's unresolved tension is whether precision medicine will become a universal standard of care or a privilege that deepens the divide between those treated with exactness and those left behind.
In the span of a single year, the FDA approved ten molecularly targeted cancer therapies — each one designed not to overwhelm the body, but to find and dismantle the specific molecular machinery driving a patient's disease. The 2026 AACR Cancer Progress Report frames this acceleration against a sobering horizon: over 626,000 projected American deaths this year, and a cancer burden expected to grow nearly a fifth by 2050. Among the approvals stands vepdegestrant, the first drug of an entirely new class — PROTACs — that commandeers the cell's own disposal system to eliminate cancerous proteins, a milestone that suggests oncology is not merely improving its tools but rethinking them. The deeper question the report leaves open is whether this precision revolution will extend to all who need it, or whether the most sophisticated medicine in history will remain unevenly distributed across the human lives it was made to save.
The American Association for Cancer Research's 2026 Cancer Progress Report arrives as a document of two truths held in tension: extraordinary scientific momentum, and the stubborn persistence of inequity.
In a single twelve-month window, the FDA approved ten molecularly targeted cancer therapies — drugs engineered to attack specific genetic vulnerabilities rather than broadly damaging healthy tissue alongside cancerous cells. The approvals span breast, lung, ovarian, prostate, brain, and blood cancers, reflecting how deeply precision medicine has taken root across oncology. The urgency behind this pace is real: more than 2.1 million new cancer diagnoses are expected in the United States in 2026, with 626,000 deaths projected for the year. By 2050, annual cases are forecast to exceed 2.5 million.
The most historically significant approval may be vepdegestrant, the first drug in a class called PROTACs — proteolysis-targeting chimeras — which work by co-opting the cell's own protein-disposal machinery to destroy the molecules fueling cancer growth. Approved in May 2026 for ESR1-mutated, estrogen receptor-positive breast cancer, it represents not an incremental step but a new category of medicine. It followed imlunestrant, approved months earlier for a similar patient population, together marking a genuine expansion of pathways into the disease.
Alongside these therapies, companion diagnostics have become inseparable from modern cancer care — tests that identify the specific mutation or biomarker a drug targets, now required for the safe use of many FDA-approved treatments. Lung cancer saw three new targeted approvals for HER2 and EGFR mutations. A first-ever systemic therapy arrived for diffuse midline glioma, a brain tumor that had previously had no targeted option. Blood cancers gained a new menin inhibitor for certain acute myeloid leukemias.
But the report does not conclude in triumph. It names what the approvals cannot yet solve: unequal access to biomarker testing, gaps between diagnosis and matched treatment, and the ongoing challenge of resistance as cancers adapt. The precision medicine revolution is real — and for those who can reach it, transformative. Whether it becomes medicine for everyone, or medicine for the fortunate, remains the question the science alone cannot answer.
The American Association for Cancer Research released its 2026 Cancer Progress Report this fall, and the document tells a story of remarkable velocity in drug development: ten new molecularly targeted cancer therapies approved by the FDA in a single twelve-month window, each one engineered to attack specific molecular vulnerabilities rather than casting a wide net across healthy tissue. The wave of approvals spans breast, lung, ovarian, prostate, brain, and blood cancers—a breadth that signals how thoroughly precision medicine has begun to reshape oncology practice.
The timing matters because the cancer burden in America is not shrinking. More than 2.1 million new diagnoses are expected in 2026 alone, with 626,000 deaths projected for the year. The trajectory is steeper still when you look forward: by 2050, annual new cases are forecast to climb above 2.5 million, a nineteen percent increase from today's numbers. Against that backdrop, the speed of these approvals reads less as a luxury and more as a race.
Among the most significant approvals was vepdegestrant, marketed as Veppanu, which arrived in May 2026 for patients with estrogen receptor-positive, HER2-negative breast cancer that carries an ESR1 mutation and has spread. What makes vepdegestrant notable is not just its efficacy but its mechanism: it belongs to an entirely new class of drugs called PROTACs—proteolysis-targeting chimeras—that work by hijacking the cell's own protein-disposal system to destroy the proteins driving cancer growth. It is the first drug of its kind to win FDA approval. Earlier, in September 2025, another oral therapy called imlunestrant, branded as Inluriyo, had been approved for ESR1-mutated breast cancer that had progressed despite endocrine therapy. These two drugs represent not incremental improvements but new pathways into the disease.
The expansion of precision treatment has made molecular testing not optional but foundational. Companion diagnostics—tests that examine tumor tissue or blood to identify the specific genetic alteration or biomarker that a given drug targets—have become the gatekeepers of modern cancer care. Unlike complementary diagnostics, which provide supporting information, companion diagnostics are now required for the safe and effective use of certain FDA-approved therapies. The Guardant360 CDx test, for instance, was approved to identify which patients with ESR1-mutated breast cancer would benefit from either imlunestrant or vepdegestrant. Similar companion diagnostics were approved alongside new treatments for HER2-mutated non-small cell lung cancer and PTEN-deficient metastatic hormone-sensitive prostate cancer. The pattern is becoming standard: drug and diagnostic arrive together, each validating the other.
Lung cancer saw particular momentum. Three new targeted therapies won approval: zongertinib and sevabertinib for advanced tumors carrying certain HER2 mutations, and sunvozertinib for tumors with EGFR exon 20 insertion mutations. In ovarian cancer, relacorilant emerged as a first-in-class glucocorticoid receptor antagonist for platinum-resistant disease. The AKT inhibitor capivasertib gained an expanded indication for PTEN-deficient prostate cancer. For rare cancers, dordaviprone became the first systemic therapy approved for diffuse midline glioma with an H3K27M mutation—a disease that had previously lacked any targeted option. Blood cancers benefited too: the menin inhibitor ziftomenib won approval for certain NPM1-mutated acute myeloid leukemias.
Yet the report does not end in celebration. Alongside the clinical advances, the AACR document names a persistent problem: disparities in access. Not all patients can reach biomarker testing. Not all who receive a diagnosis can access the matched targeted therapy. Treatment resistance also looms—even initially effective drugs can lose their power over time as cancers evolve. The approvals are real and transformative for those who can use them. The question the report leaves unresolved is whether the precision medicine revolution will reach everyone, or whether it will deepen the divide between those who can afford to be treated precisely and those who cannot.
Citazioni salienti
Companion diagnostics are required for the safe and effective use of certain FDA-approved therapies, helping identify patients most likely to benefit while sparing others ineffective treatment and potential side effects.— 2026 AACR Cancer Progress Report
Persistent barriers to precision cancer medicine include disparities in access to biomarker testing and matched targeted therapies, as well as treatment resistance that can limit long-term benefits.— 2026 AACR Cancer Progress Report
Vuoi la storia completa?
Leggi l'originale su Inside Precision Medicine ↗
Health & Medicine